Alnylam PharmaceuticalsLTS:0HD2 67 Altman Z-Score is 6.09 as of Jun. 30, 2026, which is 73% above its 10-year median of 3.52. GuruFocus rates LTS:0HD2 with a GF Score™ of 67/100 and a GF Value™ of $515.25 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 932 Biotechnology companies, Alnylam Pharmaceuticals ranks better than 68.24% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 6.09 is strong.
Alnylam Pharmaceuticals has a Altman Z-Score of 6.09, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Alnylam Pharmaceuticals's Altman Z-Score or its related term are showing as below:
LTS:0HD2'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.92 Med: 3.52 Max: 41.16
Current: 6.09
During the past 13 years, Alnylam Pharmaceuticals's highest Altman Z-Score was 41.16. The lowest was 0.92. And the median was 3.52.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HD2 vs RVMD, ONC, MRNA: Altman Z-Score Comparison
For the Biotechnology subindustry, Alnylam Pharmaceuticals's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alnylam Pharmaceuticals Altman Z-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alnylam Pharmaceuticals's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Alnylam Pharmaceuticals's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Alnylam Pharmaceuticals (LTS:0HD2) has a Altman Z-Score of 6.09 as of Jun. 30, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alnylam Pharmaceuticals and its competitors. This is 73% above median its historical median of 3.52. Over the past decade, Alnylam Pharmaceuticals' Altman Z-Score has ranged from 0.92 to 41.16. According to the industry distribution chart, Alnylam Pharmaceuticals ranks #296 out of 932 companies in the Biotechnology industry, placing it in the top 31.8%.
Is Alnylam Pharmaceuticals' Altman Z-Score too high?
Alnylam Pharmaceuticals' current Altman Z-Score of 6.09 is 73% above median its 10-year median of 3.52. Over the past 10 years, this metric has ranged from a low of 0.92 to a high of 41.16. The Biotechnology industry median Altman Z-Score is 2.57. Alnylam Pharmaceuticals' value of 6.09 is 137.4% above this industry median. Based on the distribution chart, Alnylam Pharmaceuticals ranks #296 out of 932 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Alnylam Pharmaceuticals has a GF Score™ of 67/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alnylam Pharmaceuticals' Altman Z-Score compare to RVMD and ONC?
According to the Biotechnology industry distribution chart, Alnylam Pharmaceuticals ranks #296 out of 932 companies for Altman Z-Score. This puts Alnylam Pharmaceuticals in the upper half of its industry. The industry median Altman Z-Score is 2.57. Alnylam Pharmaceuticals' value of 6.09 is 137.4% above this benchmark. Historically, Alnylam Pharmaceuticals' own Altman Z-Score has ranged from 0.92 to 41.16 over the past decade. While the company's 10-year median is 3.52 vs. the industry median of 2.57, Alnylam Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Biotechnology company?
The median Altman Z-Score among Biotechnology companies is 2.57, based on 932 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alnylam Pharmaceuticals's current Altman Z-Score of 6.09 is 137.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Alnylam Pharmaceuticals and its competitors. For the Biotechnology industry, the median Altman Z-Score is 2.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alnylam Pharmaceuticals's current Altman Z-Score is 6.09, which is 73% above median its own 10-year median of 3.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alnylam Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals (LTS:0HD2) is currently considered Significantly Undervalued. The stock's GF Value™ is $515.25, compared to a current price of $294.38 — trading 42.9% below its estimated fair value. The current Altman Z-Score is 6.09, which is 73% above median its 10-year median of 3.52 and 137.4% above the Biotechnology industry median of 2.57. Alnylam Pharmaceuticals' overall GF Score™ is 67/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Alnylam Pharmaceuticals (LTS:0HD2), the current Altman Z-Score is 6.09 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alnylam Pharmaceuticals (LTS:0HD2) Overvalued in 2026?
Based on GuruFocus' analysis, Alnylam Pharmaceuticals stock appears to be undervalued.
The current stock price of $294.38 is trading 42.9% below its estimated GF Value™ of $515.25.
GuruFocus considers Alnylam Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for LTS:0HD2:
Altman Z-Score: 6.09 (73% above median its 10-year median of 3.52)
GF Value™: $515.25 vs. price of $294.38 (42.9% below fair value)
Industry Position: 137.4% above the Biotechnology median (#296 of 932)
No single metric tells the full story. See the LTS:0HD2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
67GF Score
Get the complete analysis for LTS:0HD2
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HD2 has been successfully added to your 
